<DOC>
	<DOC>NCT01093794</DOC>
	<brief_summary>This study will test the hypothesis that the Final Market Image (FMI) sitagliptin/metformin 50 mg/500 mg and 50 mg/850 mg (Fixed Dose Combination) FDC tablet and co-administration of corresponding doses of sitagliptin and China-sourced metformin as individual tablets will be bioequivalent based on assessment of the AUC(0-t) and Cmax, for both sitagliptin and metformin.</brief_summary>
	<brief_title>Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Subject is of Chinese descent Subject is in good health Subject is a nonsmoker Subject has a history of stroke or chronic seizures Subject has a history of cancer Subject has had major surgery, donated blood or participated in another investigational study within the past 4 weeks</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Type 2 Diabetes</keyword>
</DOC>